Thomas H. Nufert

Co-founder and Chief Executive Officer

Tom Nufert

Thomas H. Nufert is the visionary entrepreneur behind Younger Phenotype. His unique perspectives on the relationship of insulin resistance to the loss of overall biological function lay at the foundation of Younger Phenotype. These perspectives derive from two major experiences:

First, in 1986, Mr. Nufert founded Thomas Research Corporation (TRC), the first company to target insulin resistance. For over three decades, Mr. Nufert has advanced this field and the hypothesis that insulin resistance underlies aging. Scientific research has now clearly established insulin resistance as central to aging.

Second, for 35 years he served as a biomedical consultant assisting physicians and their patients suffering from intractable diseases and conditions. These consulting services involved acquiring deep knowledge in multiple biomedical fields, sophisticated techniques of knowledge acquisition, collaborations with physicians and academic investigators, and hands-on work with patients.

Mr. Nufert also advances important understandings of the role of the hypothalamus in relationship to the neuroendocrine mechanisms of aging as a Research Scientist at the Center for Research and Education on Aging (CREA), University of California, Berkeley.

Prior to Younger Phenotype, Mr. Nufert co-founded Nanopolymer Systems, a nanotechnology company, served as its Vice-President of Corporate Development and remains a board member. He was a co-founder and Vice-President of Research and Development of Array BioSciences, Inc. (Oakland, CA). He served as the Chairman and CEO of TRC (Hayward, CA). TRC’s science attracted a number of scientists including Nobel laureates Melvin Calvin and Henry Taube. He is a co-inventor on a number of patents and patent applications.

He founded Thomas Laboratories, which developed Arth-Relief™, a novel, copper-containing topical analgesic OTC drug. Mr. Nufert was responsible for all aspects of product and business development from product inception through regulatory affairs, analytical and validation processes, distribution, marketing and sales.

He has been fortunate to have an unusual education. This includes formal interdisciplinary studies (BA, The Evergreen State College), valuable informal mentoring from Nobel laureates and research-oriented physicians, and decades of self-learning as an autodidact. In addition, he studied economics, food science and physiological psychology at University of Illinois (Springfield) and electronics at DeVry University (Chicago). He has also worked for Perkin Elmer Corporation (Coleman Instrument Division).